Sorafenib and Temsirolimus in Treating Patients With Unresectable or Metastatic Solid Tumors

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

April 30, 2007

Study Completion Date

April 30, 2007

Conditions

Unspecified Adult Solid Tumor, Protocol Specific

Interventions

DRUG

sorafenib tosylate

Given orally

DRUG

temsirolimus

Given IV

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

Cancer Therapy and Research Center at The UT Health Science Center at San Antonio, San Antonio

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH

NCT00255658 - Sorafenib and Temsirolimus in Treating Patients With Unresectable or Metastatic Solid Tumors | Biotech Hunter | Biotech Hunter